November 12, 2020
Revolution Medicines Reports Third Quarter 2020 Financial Results and Update on Corporate Progress
October 24, 2020
Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers
October 12, 2020
Revolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid Tumors
September 16, 2020
Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors
September 9, 2020
Revolution Medicines to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 8, 2020
Revolution Medicines to Participate in 2nd Annual RAS-Targeted Drug Development Conference
August 10, 2020
Revolution Medicines Reports Second Quarter 2020 Financial Results and Provides Update on Corporate Progress
July 13, 2020
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
July 8, 2020
Revolution Medicines Announces Pricing of $156.0 Million Public Offering of Common Stock
July 6, 2020
Revolution Medicines Announces Proposed Public Offering of Common Stock